Voyager Therapeutics (VYGR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$208.9 million.
- Voyager Therapeutics' Enterprise Value rose 3950.37% to -$208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$208.9 million, marking a year-over-year increase of 3950.37%. This contributed to the annual value of -$266.7 million for FY2024, which is 1551.01% down from last year.
- Latest data reveals that Voyager Therapeutics reported Enterprise Value of -$208.9 million as of Q3 2025, which was up 3950.37% from -$215.6 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Enterprise Value ranged from a high of -$118.8 million in Q4 2022 and a low of -$399.6 million during Q1 2024
- For the 5-year period, Voyager Therapeutics' Enterprise Value averaged around -$220.9 million, with its median value being -$215.6 million (2025).
- As far as peak fluctuations go, Voyager Therapeutics' Enterprise Value crashed by 9426.07% in 2023, and later skyrocketed by 4189.2% in 2025.
- Over the past 5 years, Voyager Therapeutics' Enterprise Value (Quarter) stood at -$132.5 million in 2021, then grew by 10.33% to -$118.8 million in 2022, then tumbled by 94.26% to -$230.9 million in 2023, then dropped by 15.51% to -$266.7 million in 2024, then grew by 21.66% to -$208.9 million in 2025.
- Its last three reported values are -$208.9 million in Q3 2025, -$215.6 million for Q2 2025, and -$236.0 million during Q1 2025.